Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mucos pharma gmbh & co. kg - all-rac-alpha-tocopherolacetat (ph.eur.), colecalciferol, retinolpalmitat - emulsion - all-rac-alpha-tocopherolacetat (ph.eur.) 25.g; colecalciferol 250.mg; retinolpalmitat 55.g

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

bundesamt für verbraucherschutz und lebensmittelsicherheit (bvl) dienstsitz berlin (8054886) - glucose - lösung - teil 1 - lösung; glucose (12829) 100 gramm - rind; hund; schwein; pferd; ziege; schaf; katze

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

b. braun melsungen ag - levoglucose 50.g - lösung

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

clintec gmbh & co.ohg [hist] - levoglucose 50.g - lösung

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

löwen-apotheke sylvia maaß - glucose - lösung - glucose 50.g

Sviss - þýska - Swissmedic (Swiss Agency for Therapeutic Products)

desitin pharma gmbh - levetiracetamum - lösung zum einnehmen - levetiracetamum 100 mg, acidum citricum monohydricum, natrii hydroxidum, aqua purificata, aromatica (traube), acesulfamum kalicum, propylis parahydroxybenzoas 0.266 mg, e 218 1.43 mg, ad solutionem pro 1 ml corresp. natrium 0.29 mg et kalium 3.1 mg. - antiepileptikum - synthetika

Evrópusambandið - þýska - EMA (European Medicines Agency)

intervet international b.v. - live attenuated canine distemper virus strain onderstepoort: 105.1 – 106.5 tcid50, live recombinant canine parvovirus strain 630a: 105.1 – 106.7 tcid50 - immunologische für canidae - dogs (small) - for the active immunisation of puppies from 4 weeks of age onwards to prevent clinical signs and mortality of canine distemper virus infection and canine parvovirus infection and to prevent viral excretion following canine distemper virus infection and following canine parvovirus infection.

Evrópusambandið - þýska - EMA (European Medicines Agency)

intervet international b.v. - zell-assoziierten live rekombinanten türkei herpesvirus (stamm hvp360), ausgedrückt durch die fusion protein von nd-virus und das vp2-protein des ibd-virus - vogel-herpesvirus (marek ' s disease) + avian infectious bursal disease virus (gumboro-krankheit) + newcastle-krankheit-virus/paramyxovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Þýskaland - þýska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

intervet deutschland gmbh (3067358) - felines calicivirus, stamm f9, lebend; felines rhinotracheitisvirus, stamm g2620a, lebend; felines panleukopenievirus, stamm mw-1, lebend - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - felines calicivirus, stamm f9, lebend (35276) 0,6628 pocken- und plaque-bildende einheit; felines rhinotracheitisvirus, stamm g2620a, lebend (35302) 0,716 pocken- und plaque-bildende einheit; felines panleukopenievirus, stamm mw-1, lebend (35297) 0,6335 gewebekultur-infektiöse-dosis 50% - katze

Evrópusambandið - þýska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.